Abbott taps better sentiment to fund purchase of St Jude
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
New York
ABBOTT Laboratories took advantage of a post-election rally in healthcare debt to announce a US$15.1 billion bond on Thurs-day as it sought to fund its US$25 billion acquisition of rival St Jude Medical.
Changing sentiment towards healthcare companies following Donald Trump's surprise electoral victory was seen benefiting the medical device maker, which has been struggling to carry out its aggressive expansion plans.
Share with us your feedback on BT's products and services
TRENDING NOW
Japan stocks look set for new highs in 2025 on earnings, reform
Beijing’s calculated silence on the Iran war
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Richard Eu on how core values, customers keep Singapore’s TCM chain Eu Yan Sang relevant
